Zymo Research & BluMaiden Biosciences Announce Partnership to Provide Clinical Trial Analytics and Reporting Services to the Pharmaceutical Sector

Irvine, CA (October 1, 2024) — Zymo Research Corporation and BluMaiden Biosciences are joining forces to offer end-to-end clinical trial analytics and reporting services based on the human microbiome. This partnership is poised to revolutionize clinical insights and decision-making for the pharma industry with the aim of enhancing therapeutic efficacy and commercial lifespan. The partnership combines Zymo Research's expertise in sample preparation and next-generation sequencing with BluMaiden's advanced bioinformatics capabilities via the proprietary KEYSTONE AI analytical platform, creating a seamless solution for exploring the human microbiome to uncover clinical insights into health and disease. These insights include, but are not limited to, endpoint optimization, drug responder vs. non-responder prediction, and patient enrichment and stratification.

The joint service will cover every stage of human microbiome analysis, including fit-for-purpose sample collection, nucleic acid purification, next-generation sequencing, sophisticated bioinformatics data analysis, and detailed clinical trial reporting. The new service is designed to be applicable across entire trial cohorts, spanning Phase 1, 2, 3, and 4 clinical trials, and can be applied to a broad range of disease indications and intervention modalities, including those where microbiome data analysis was not previously considered. The reports can inform early pilot analysis, while also being applicable in subsequent pivotal Phase 2 and 3 clinical trials. Additionally, the pharma services can be applied retrospectively, leveraging raw sequence data and metadata for re-analysis.

This comprehensive approach is designed to provide pharma clients with easy, affordable, and fast access to high-quality clinical insights, aiming to fast-track market launch and extend the commercial lifespan of therapeutics.

Keith Booher, PhD, Director of Research Services at Zymo Research Corporation, elaborated on the strategic significance of the partnership and each company’s commitment to advancing microbiome-based discovery. “By combining Zymo Research’s strengths with BluMaiden Biosciences, we are not only enhancing our service offerings but also setting a new standard for microbiome data analysis. This collaboration allows us to deliver an unparalleled level of accuracy and efficiency, supporting our clients' research with the most comprehensive insights available.”

Damien Keogh, PhD, CEO and Director of BluMaiden Biosciences, also commented on the organizations’ shared vision of supporting the pharma sector with a complete solution for human microbiome analysis. Said Keogh, “We are excited to work with Zymo Research to bring this innovative pharma service to the market. Our shared commitment to excellence and innovation will enable us to meet the high-quality and rapidly evolving needs of the pharma sector, providing a novel application of microbiome-based data, translating these insights into patient-specific clinical outcomes.”

The new pharma service is set to be available in both Europe and North America starting at the end of Q3 2024. Both companies are confident that this collaboration will greatly benefit pharma companies and others working to develop novel therapeutics.

Learn more about Zymo Research’s Microbiome Sequencing Services

About BluMaiden Biosciences

BluMaiden Biosciences, a Singapore-headquartered biotech firm with a global presence, is a data-driven innovator producing actionable clinical insights to enhance clinical trial decision-making, commercialized through its Pharma Service. The company also identifies licensable small molecule drugs through its flagship platform MAIDEN, which couples AI-powered computational biology with computational chemistry to mine human clinical data for novel therapeutics from within the human body.

BluMaiden Biosciences | Singapore | www.blumaiden.com | Follow BluMaiden on LinkedIn

About Zymo Research Corporation

Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo Research is dedicated to developing innovative solutions that address complex scientific challenges.

Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, nucleic acid purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.

In addition to its cutting-edge technologies, Zymo Research is committed to sustainability. By engineering environmentally friendly solutions, the company strives to reduce waste and contribute to a more sustainable future through scientific innovation.

Follow Zymo Research on Facebook, LinkedIn, X (Twitter), and Instagram.

Zymo Research | 17062 Murphy Ave., Irvine, CA 92614 | https://www.zymoresearch.com | (949) 679-1190

October 01, 2024